arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

Rapport Therapeutics, Inc.

RAPP

$41.51 ▲ +1.89 (+4.76%) at close

15 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

Rapport Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.0B

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -11.4% ↘

FCF / Share $-0.87 ↘

Trailing P/E —

Price / Book 4.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-19.86M

↑ +17.5% —

FCF / Share Free cash flow per share

$-0.87

↓ -23.6% —

Health Breakdown

Returns

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-58.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	38.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-491.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-42.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	55.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	93.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	98.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	91.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	61.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	17.5% Good ↑ Good Improving Year-over-year change in net income	17.5% Good ↑ Good Improving Year-over-year change in net income	-69.0% Weak ↓ Weak Declining Year-over-year change in net income	-6.1% Weak ↑ Weak Improving Year-over-year change in net income	-6.1% Weak ↑ Weak Improving Year-over-year change in net income	-6.1% Weak ↑ Weak Improving Year-over-year change in net income	-47.8% Weak ↑ Weak Improving Year-over-year change in net income	-268.8% Weak Weak Year-over-year change in net income	-268.8% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	-23.6% Weak Weak Year-over-year change in free cash flow	52.2% Excellent Excellent Year-over-year change in free cash flow	—	—	—	93.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Operating Margin (%) (%)	—	-121.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-907%)	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	—	—	—	—	—	—	—	—	—	—	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	-99.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-927%)	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	-65.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	2.09x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-11.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-4.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-7.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	34.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	57.7% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	72.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	70.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-13.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-5.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-9.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-6.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-9.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-4.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	-7.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-146%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-9.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-161%)	-8.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-156%)	-6.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-7.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-147%)	-6.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-145%)	57.2% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+281%)	52.7% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+252%)	46.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+212%)	65.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+334%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-63.61M	$-78.06M	$-52.65M	$-251.36M	$-55.07M	$-57.60M	$-56.80M	$-39.31M	$-110.16M	$-74.27M	$-70.17M	$-159.41M	$-79.53M	—	—

📊 What does each share earn? 6 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.00	$0.42	—	—	$0.00	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.19	$-0.42	$-0.71	$-0.71	$-0.75	$-0.68	$-0.12	$-0.50	$-1.70	$-11.07	$-8.38	$-5.70	$-4.45	—	—
Free Cash Flow per Share (USD)	$-0.87	$-0.28	—	$-0.46	$-0.71	$-0.58	—	—	—	$-9.13	—	$-3.58	—	—	—
Book Value per Share (USD)	$8.82	$9.86	$10.15	$10.74	$7.43	$7.83	$8.35	$8.83	$9.21	$-19.36	$-6.15	$-8.58	$-6.55	—	—
Tangible Book Value per Share (USD)	$8.82	$9.86	$10.15	$10.74	$7.43	$7.83	$8.35	$8.83	$9.21	$-19.36	$-6.15	$-8.58	$-6.55	—	—
Basic Weighted Avg Shares (shares)	47.47M	47.24M	—	37.93M	35.44M	35.27M	—	34.86M	10.67M	2.05M	—	1.53M	1.44M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$418.43M	$466.80M	$479.51M	$506.34M	—	$281.58M	$301.04M	$318.84M	$332.57M	—	$142.07M	—	—	—	—
Total Equity (USD)	$422.93M	$471.51M	$484.65M	$511.62M	$263.51M	$285.84M	$305.43M	$323.11M	$336.89M	$-39.63M	$-25.63M	$-13.12M	$-9.43M	$-4.00M	$-10.06M

📋 What is driving earnings? 4 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$20.00M	—	—	$0.00	—	—	—	—	—	—	—	—	—	—
Depreciation Expense (USD)	$212.00K	$227.00K	$265.00K	$256.00K	$252.00K	$244.00K	$260.00K	$200.00K	$200.00K	$152.00K	$53.00K	$23.00K	—	—	—
Net Income, GAAP (USD)	$-19.86M	$-19.86M	$-33.76M	$-24.06M	$-24.06M	$-24.06M	$-19.98M	$-22.67M	$-22.67M	$-22.67M	$-13.52M	$-6.15M	$-6.15M	—	—
Operating Cash Flow (USD)	$-41.45M	$-13.06M	$-24.70M	$-17.46M	$-25.07M	$-20.24M	$-14.45M	—	—	$-17.61M	$-10.36M	$-5.42M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters

Rapport Therapeutics, Inc.

Analytical Summary

15-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare RAPP with peers